Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Vitrafy Targets US Health Market as Shareholders Back Placement Facility

VFY: $2.65 +3.92% · MC: $165M

Vitrafy Life Sciences is focusing its direct commercial efforts on US human health while pursuing animal reproduction through its partnership with IMV Technologies. The company expects short-term costs to rise as it invests in validation, manufacturing and delivery of initial medical devices, and held approximately $38 million in cash and term deposits at the end of September. At its annual meeting, shareholders approved an additional placement facility and performance rights for CEO Brent Owens, and elected Jeannette Joughin and re-elected Kate Munnings as directors.

Source announcements: 2026-11-17 12:27 to 2026-11-17 15:42 Sydney time
Story updated 2026-11-17 16:14 Sydney time
Sources2026 Annual General Meeting Addresses & PresentationResults of 2026 Annual General Meeting
Comments